Edition:
United States

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

181.13USD
18 Jul 2018
Change (% chg)

$-1.46 (-0.80%)
Prev Close
$182.59
Open
$182.00
Day's High
$182.34
Day's Low
$180.71
Volume
316,837
Avg. Vol
573,955
52-wk High
$183.36
52-wk Low
$127.68

Select another date:

Thu, Apr 26 2018

Vertex Pharma profit tops estimates on strong launch of new CF drug

Vertex Pharmaceuticals Inc topped analysts' forecasts for quarterly profit on Thursday, led by stronger-than expected sales of its latest cystic fibrosis drug as well as double-digit growth in sales of older treatments.

UPDATE 2-Vertex Pharma profit tops estimates on strong launch of new CF drug

* New CF drug Symdeko Q1 sales $34 mln easily tops expectations

BRIEF-Vertex Initiates Phase 3 Studies Of Vx-445, Tezacaftor And Ivacaftor

* VERTEX INITIATES PHASE 3 STUDIES OF VX-445, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS

CORRECTED-Vertex Pharma's quarterly profit falls 15.1 percent

April 26 Vertex Pharmaceuticals Inc's quarterly profit fell 15.1 percent, hurt by higher research and development spending.

BRIEF-Vertex Pharmaceuticals Inc Reports Qtrly EPS Of $0.81

* COMPANY REITERATES FULL-YEAR 2018 TOTAL CF PRODUCT REVENUE GUIDANCE OF $2.65 BILLION TO $2.80 BILLION

BRIEF-Vertex Pharma CEO's FY 2017 Total Compensation $17.3 Mln

* VERTEX PHARMACEUTICALS INC SAYS CEO JEFFREY LEIDEN'S FY 2017 TOTAL COMPENSATION WAS $17.3 MILLION VERSUS $17.4 MILLION IN FY 2016 - SEC FILING Source text (https://bit.ly/2JVKbq6) Further company coverage:

BRIEF-Veritas Pharma Enters Into Share Purchase Agreement With 3 Carbon Extractions Inc.

* VERITAS PHARMA ENTERS INTO SHARE PURCHASE AGREEMENT WITH 3 CARBON EXTRACTIONS INC. Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Vertex Pharmaceuticals CEO Leiden's 2017 Compensation Was $17.2 Mln

* VERTEX PHARMACEUTICALS INC - CEO JEFFREY LEIDEN'S 2017 TOTAL COMPENSATION WAS $17.2 MLN VS $17.4 MLN IN 2016 - SEC FILING Source text - https://bit.ly/2uQs5Cx Further company coverage:

BRIEF-Q-State Biosciences Says Entered Strategic Collaboration With Vertex Pharmaceuticals

* PER TERMS OF DEAL, CO TO RECEIVE UPFRONT & RESEARCH SUPPORT, ELIGIBLE TO RECEIVE RESEARCH, DEVELOPMENT & SALES MILESTONES

BRIEF-Vertex Appoints Reshma Kewalramani As Chief Medical Officer

* VERTEX APPOINTS RESHMA KEWALRAMANI, M.D., AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:

Select another date: